SaaS · Energy
More than three years after the launch of a public lighting project supported by MONUSCO, residents of Mahagi continue to feel its benefits. Improved security, economic activities extending into the night, and easier nighttime travel: in this town in northeastern Ituri Province, solar streetlights have transformed the daily lives of many families. The initiative also illustrates the Mission’s commitment to reducing community violence and promoting stabilization.
We visited the area to see the impact firsthand.
Report
It is 7:30 p.m. in the town of Mahagi. Night has fallen over the administrative center of the territory of the same name, located approximately 185 kilometers north of Bunia, near the border with Uganda.
Although the sun disappeared below the horizon some time ago, commercial and social activities show no signs of slowing down.
In the past, darkness encouraged acts of banditry, exposed residents to assaults, and increased the risk of road accidents. Women returning home late from the market, small-scale traders, and young people were among those most vulnerable to insecurity.
“With the lights, we are no longer afraid”
For Gisèle, a resident of Mahagi, the benefits are primarily related to security.
“The lighting here helps keep us safe. Many women work at the market at night and return home late. With the lights, we feel more comfortable. We are not afraid,” she says.
Her simple words convey just how important this infrastructure is to local residents.
For Innocent Wabekudu, coordinator of the Mahagi Civil Society Forces Vives, the project has also had a noticeable impact on security.
“This project has helped combat nighttime crime and reduce the risk of road accidents. Today, the roads are lit, residents can move around more easily, and traders can continue their activities until late in the evening. In the past, darkness was a real security problem for the population. With these streetlights, we are seeing an improvement, and people can move around with greater peace of mind, almost as if it were broad daylight. This is a very important change for our community, and we greatly appreciate it,” he explains.
For women selling food products, small-scale traders, and young people who depend on informal economic activities for their livelihoods, having a few extra hours to work can make a significant difference to their income.
Security and community empowerment
The public lighting project, funded to the tune of US$93,630, included the installation of 66 solar streetlights along several kilometers of roads.
More broadly, public lighting initiatives have led to the installation of 231 streetlights in several towns across Mahagi Territory, including Mahagi-Centre, Nyoka, Amée, and Ngote.
At the same time, the beneficiaries received vocational training in the installation of photovoltaic electrical systems. Upon completion of the project, they were awarded certificates. This provided them with professional skills that could support their socioeconomic integration well beyond the duration of the project.
The project therefore pursued a dual objective: to provide vulnerable people with immediate income-generating and learning opportunities while equipping the community with infrastructure designed to sustainably improve security and living conditions.
This initiative highlights an essential aspect of MONUSCO’s mandate to protect civilians: beyond responding immediately to security threats, the Mission also contributes to creating an environment in which people can live safely, pursue economic activities, and sustainably improve their living conditions.
Distributed by APO Group on behalf of Mission de l'Organisation des Nations unies en République démocratique du Congo (MONUSCO).
Oct 16 · 10:31·APO Group
Finance · Healthcare
Hong Kong/Jakarta, Oct 16, 2026 - Black Spade is pleased to announce its role alongside Kingsmen Xperience in bringing Netflix’s Squid Game: The Experience to Indonesia with local operator SideQuest Worlds, part of PT Vista Adhya Paragon, bringing expertise in media and immersive entertainment.
Opening on 16 October 2026 at Agora Mall in Jakarta’s Thamrin Nine complex, home to Indonesia’s tallest building, it is the first Squid Game: The Experience in Southeast Asia, bringing the acclaimed series to life through immersive environments and interactive challenges.
Spanning more than 1,900 square metres, the Jakarta attraction features games inspired by the series, themed environments, photo zones and food and beverage offerings. Following editions in New York, Madrid, Seoul, London, Sydney and Tokyo, it brings the global entertainment experience to Indonesian audiences and visitors from across the region.
Photo Caption:
From the left: Jonny Moran (Netflix), Corey Redmond (Kingsmen), project representative, Hardie Widarma (SideQuest Worlds), Andrew Chin (SideQuest Worlds), and Dennis Tam (President and CEO of Black Spade)
About Black Spade Capital Limited
Black Spade Capital Limited is an established family office that manages the private investments of Mr. Lawrence Ho. Headquartered in Hong Kong, its global portfolio consists of a wide spectrum of cross-border investments as it consistently seeks to add new projects and opportunities to its investment mix. Black Spade’s investment strategy maximizes coverage of geographic regions and sectors whilst maintaining a portfolio of diversified asset classes, ranging from equity, fixed income, medical technology, leisure and culture, green energy, real estate to Pre-IPO investments. In August 2023, Black Spade Acquisition Co, a blank check company (SPAC) sponsored by Black Spade, completed a US$23 billion business combination with VinFast Auto Ltd. The second SPAC of Black Spade, Black Spade Acquisition II Co, completed a business combination with global media and entertainment powerhouse The Generation Essentials Group in about 9 months’ time in June 2025. Its third SPAC, Black Spade Acquisition III Co in August 2026, announced the signing of a business combination agreement with Astrum Space Inc, a satellite communications company developing a wholesale satellite-to-device (“S2D”) broadcast and data-distribution network.
Media Enquiries:
Strategic Financial Relations Limited
Vicky Lee
Tel: +852 2864 4834
Email: vicky.lee@sprg.com.hk
Iris Au Yeung
Tel: +852 2114 4913
Email: iris.auyeung@sprg.com.hk
Website: www.sprg.com.hk
Oct 16 · 09:57·ACN Newswire
AI · SaaS
Boca Raton, Florida Friday Oct 16, 2026 @ 5:00 AM Eastern —
AgeReverse, a Canadian longevity company focused on healthy aging and cellular vitality, today announced that its flagship RESURGE formulation is now available to U.S. consumers on Amazon, marking another significant step in the company’s expansion into the American market.
The Amazon launch follows a series of U.S. expansion initiatives for AgeReverse, including the company’s recent participation in the ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida. With RESURGE now available through one of the country’s largest online marketplaces, AgeReverse is expanding consumer access while continuing to introduce its broader science-first approach to healthy aging.
“Making RESURGE available on Amazon is an important milestone for AgeReverse because it gives consumers across the United States convenient access to our first product in the market,” said Kubi Turkmen, Founder and CEO of AgeReverse. “We are building AgeReverse around a comprehensive view of healthy aging, and RESURGE represents the internal wellness component of that larger vision.”
AgeReverse developed RESURGE around the scientific concept of the 12 Hallmarks of Aging, a framework used by researchers to describe interconnected biological processes associated with aging. Rather than focusing on a single ingredient or isolated wellness benefit, the company designed RESURGE as a multi-ingredient formulation intended to support multiple aspects of healthy aging and everyday wellness.
The 90-capsule formulation combines ingredients including NMN, Resveratrol, Quercetin, Fisetin, CoQ10, Astragalus Extract, Hyaluronic Acid, Aronia Extract and Noni Berry into a simplified three-capsule daily regimen.
Key features and benefits of RESURGE include:
Designed to support all 12 Hallmarks of Aging through a comprehensive longevity-focused formulation
Combines ingredients including NMN, Resveratrol, Quercetin, Fisetin, CoQ10, Astragalus Extract, Hyaluronic Acid, Aronia Extract, and Noni Berry
Provides antioxidant support to help protect cells from oxidative stress and free radical damage
Supports nutrient metabolism and overall cellular health
Helps support cardiovascular health and immune system function
Supports collagen formation, connective tissue development, and skin quality
Helps maintain healthy joints, cartilage, bones, gums, and connective tissue
Includes herbal ingredients traditionally used as capillary and blood vessel protectants
Consolidates what the company describes as 15+ supplement protocols into a simplified 3-capsule daily routine
Manufactured in GMP-certified facilities in Ontario, Canada using vegan capsules
Registered as a Natural Health Product with Health Canada
The Amazon availability also advances a broader AgeReverse strategy that extends beyond nutritional wellness. The company is developing a complete range of healthy aging products and technologies intended to address both internal wellness and external skin aging.
The planned AgeReverse product range includes a Bioage Test, daily skincare products developed around the 12 Hallmarks of Aging, professional mesotherapy products for the medical aesthetics and medspa markets, and non-invasive mesotherapy technology designed to deliver skincare formulations without needles.
“Our vision has always extended beyond one product,” Turkmen added. “We believe healthy aging should be approached from both inside and outside the body. RESURGE gives U.S. consumers an introduction to that philosophy, and Amazon gives us an important channel for building awareness and accessibility as the AgeReverse product range grows.”
AgeReverse is positioning its expanding portfolio around a science-first philosophy aimed at men and women interested in longevity, healthy aging, cellular wellness and maintaining vitality as they age. The company plans to serve both consumers and professionals in the medical aesthetics market as additional products are introduced.
RESURGE is now available to U.S. consumers on Amazon. AgeReverse plans to continue expanding its product range and U.S. presence as additional products become available.
Visit the AgeReverse Website and follow the company on Instagram and LinkedIn.
About AgeReverse
AgeReverse is a Canada-based longevity wellness company focused on developing science-driven products designed to support healthy aging and cellular vitality. Founded by Kubi Turkmen, who has more than 30 years of experience in anti-aging innovation, the company’s approach combines longevity research, telomere science, and wellness innovation to create comprehensive healthy aging solutions. The company’s expanding AgeReverse platform includes longevity supplements and other wellness technologies designed to support multiple biological pathways associated with aging and long-term vitality. Products are manufactured in GMP-certified facilities in Ontario, Canada.
FDA Disclaimer
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Oct 16 · 09:00·Newsworthy.ai
AI · Healthcare
FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favourable safety profile, regardless of TED activity or duration1,2
Enspryng (satralizumab) represents an important advance for people with TED, offering the first at-home SC treatment option every four weeks during maintenance phase, allowing for greater flexibility in how treatment is administered1
Enspryng is an anti-IL-6R mAb using novel recycling antibody technology designed to inhibit IL-6 signalling upstream of autoantibody-driven pathology2,3
TED is a rare autoimmune disease affecting approximately 155 out of every 100,000 people in the US that can lead to facial disfigurement and vision-threatening complications if left untreated3-7
Basel, 16 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Enspryng® (satralizumab) for the treatment of adults with thyroid eye disease (TED), providing patients with the first and only at-home subcutaneous treatment option. Enspryng can be administered by a person living with TED or a caregiver following training from a healthcare provider.1
“Today’s FDA approval of Enspryng provides an important new option for people with thyroid eye disease, who have long faced limited treatment choices,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “As the first subcutaneous treatment for this condition, Enspryng offers a positive safety and efficacy profile and the potential for at-home administration.”
"Treating thyroid eye disease requires balancing efficacy, safety, and the practical realities of long-term treatment,” said César A. Briceño, MD, Clinical Trial Investigator and Associate Professor of Ophthalmology at the Scheie Eye Institute, University of Pennsylvania. “As a clinical trial investigator, I have seen firsthand the potential of targeted therapies such as Enspryng. The availability of an effective subcutaneous treatment option could provide greater flexibility for both patients and physicians while reducing the logistical burden associated with infusion-based therapies. Enspryng has the potential to meaningfully expand our therapeutic options for patients with thyroid eye disease."
The totality of data from the pivotal Phase III SatraGO programme (SatraGO-1 and SatraGO-2) provided clinically meaningful improvements in patients with TED.1,2 While SatraGO-1 did not meet its pre-specified primary efficacy endpoint at Week 24, SatraGO-2 achieved significant and clinically meaningful difference in proptosis response (52.9% in the Enspryng group compared to 23.4% in the placebo group) and in diplopia reduction (60.7% in the Enspryng group compared to 25.8% in the placebo group) in the active TED population.1,2 Consistent results were achieved in the overall population (including both active and chronic patients) in SatraGO-2.1,2 No new safety signals were identified in the SatraGO trials, with Enspryng’s safety profile consistent with its known profile in neuromyelitis optica spectrum disorder (NMOSD).1,2 Full results were shared at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Fall Scientific Symposium in October 2025.2
“Thyroid eye disease not only affects a person’s eyes through bulging and vision problems, but it also takes a profound emotional toll on confidence, identity, relationships and daily life,” said Christine Gustafson, Chief Executive Officer of the TED Community Organization. “Until now, our community has had very limited choices. The approval of Enspryng represents a critical turning point through a convenient, targeted option.”
The approval in TED, following a priority review designation, marks the second indication for Enspryng, following an approval in neuromyelitis optica spectrum disorder (NMOSD) in 2020.1,8,9 This follows a recent acceptance by the FDA for priority review in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).10 Enspryng is also being studied in additional neurological autoimmune and inflammatory diseases that may benefit from inhibition of IL-6 mediated signalling.
About SatraGO-1 and -2
SatraGO-1 (NCT05987423) and -2 (NCT06106828) are identically designed, Phase III, randomised, placebo-controlled, multicentre studies to determine the efficacy, durability and tolerability of Enspryng for the treatment of adults with active, moderate‑to‑severe TED and chronic TED. The studies enrolled a total of 258 patients from 19 countries. Participants were randomised 1:1 to receive Enspryng or placebo. The primary endpoints were the proportion of participants with active, moderate-to-severe TED who achieved an at least 2 mm reduction in proptosis in the study eye from baseline at week 24.2,3
About thyroid eye disease (TED)
TED, also known as Graves’ ophthalmopathy, is a complex inflammatory autoimmune disease, affecting the area around the eyes and the eyes themselves, that can be sight-threatening, debilitating and disfiguring.4,5 The most common symptoms are redness, swelling of the eyes, eyelid retraction, appearance of a stare, bulging of one or both eyes (proptosis), double vision (diplopia) and pain.4,6
TED is a progressive rare disease that affects approximately 155 people out of every 100,000.3-5,7 It most commonly occurs in people with hyperthyroidism, approximately 50% of whom experience at least mild TED, but it can also affect people with hypothyroidism or normal thyroid function.4,11
Despite existing approved treatments for TED, a medical need remains for therapies that are effective, well-tolerated, and have a convenient route of administration.3
About Enspryng® (satralizumab)
Enspryng, developed by Chugai, a member of the Roche Group, is a humanised monoclonal antibody that is designed to bind to both soluble and membrane-bound interleukin-6 receptors (IL-6R), thereby inhibiting IL-6 mediated signalling, a known key pathway involved in inflammation. Enspryng incorporates Chugai’s proprietary antibody recycling technology, which enables pH-dependent binding to IL-6R and repeated engagement of the target, extending antibody circulation and supporting sustained inhibition of IL-6 mediated signalling.1-3,12
Enspryng is the first and only IL-6R inhibitor treatment currently approved in approximately 90 countries for neuromyelitis optica spectrum disorder (NMOSD), including in the European Union and United States, with a well established safety profile in over 16,000 patients.1,13
Roche is committed to developing Enspryng in additional neurological autoimmune and inflammatory diseases that may benefit from inhibition of IL-6 mediated signalling, including autoimmune encephalitis (AIE) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The FDA granted priority review of the Enspryng supplemental Biologics License Application (sBLA) for MOGAD in September 2026 with an approval decision expected in January 2027.10
Enspryng has orphan drug designation in the United States and European Union for NMOSD and MOGAD and in the United States for anti-NMDA receptor autoimmune encephalitis (anti-NMDAR AIE) and leucine-rich glioma-inactivated 1 autoimmune encephalitis (LGI1 AIE).
About Roche in Ophthalmology
At Roche, we are on a mission to save and restore eyesight. Over 330 million people around the world are blind, or living with vision loss, creating a profound personal and socioeconomic burden. With the broadest pipeline in Ophthalmology, we continue to invest at scale to redefine what is medically possible in eye care.
Our comprehensive ophthalmology pipeline integrates diverse targets, advanced delivery systems, cell and gene therapies, and AI-augmented imaging capabilities, targeting multiple vision-threatening conditions, including retinal vascular and diabetic eye diseases, geographic atrophy, and autoimmune conditions, such as thyroid eye disease and uveitic macular edema.
About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.
Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.
Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
References
[1] Enspryng (satralizumab) Prescribing Information.
[2] Briceño C, et al. Primary Results of the Phase 3 SatraGO-1 and SatraGO-2 Trials: Efficacy and Safety of Satralizumab in Thyroid Eye Disease. Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Fall Scientific Symposium, October 16–17, 2025.
[3] Ezra D, Collins A, Haskova Z, et al. Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials. Ophthalmol Ther. 2025;14(12):3119-3132. doi:10.1007/s40123-025-01255-3
[4] McAlinden C. An overview of thyroid eye disease. Eye Vis (Lond). 2014;1:9. doi:10.1186/s40662-014-0009-8
[5] Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy. Front Endocrinol (Lausanne). 2020;11:615993. doi:10.3389/fendo.2020.615993
[6] Thyroid eye disease. British Thyroid Foundation. Accessed October 12, 2026. https://www.btf-thyroid.org/thyroid-eye-disease-leaflet
[7] Moledina M, Damato EM, Lee V. The changing landscape of thyroid eye disease: current clinical advances and future outlook. Eye (Lond). 2024;38(8):1425-1437. doi:10.1038/s41433-024-02967-9
[8] FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED). Accessed October 12, 2026. https://www.roche.com/media/releases/med-cor-2026-06-30
[9] FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD). Accessed October 12, 2026. https://www.roche.com/media/releases/med-cor-2020-08-17
[10] U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments. Accessed October 12, 2026. https://www.roche.com/media/releases/med-cor-2026-09-10
[11] Bahn RS. Emerging pharmacotherapy for treatment of Graves' disease. Expert Rev Clin Pharmacol. 2012;5(6):605-607. doi:10.1586/ecp.12.54
[12] Heo YA. Satralizumab: First Approval. Drugs. 2020;80(14):1477-1482. doi:10.1007/s40265-020-01380-2
[13] Enspryng (satralizumab) Summary of Product Characteristics. Accessed October 12, 2026. https://www.ema.europa.eu/en/documents/product-information/enspryng-epar-product-information_en.pdf
Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com
Tristan Schmitz
Phone: +41 79 529 70 35Lorena Corfas
Phone: +41 79 568 24 95
Simon Goldsborough
Phone: +44 797 32 72 915Karsten Kleine
Phone: +41 79 461 86 83
Kirti Pandey
Phone: +41 79 398 38 53Yvette Petillon
Phone: +41 79 961 92 50
Irène Stephan
Phone: +41 79 377 83 75Albert Thottiyil
Phone: +41 79 775 66 12
Roche Investor Relations
Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.comDr Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
Attachment
Media & investor Release Enspryng TED FDA English
Oct 16 · 05:00·Roche
SaaS · Food & drink
SHANGHAI, Oct. 15, 2026 -- China released GB 7718-2025 on March 16, 2025, with implementation set for March 16, 2027. As the food and pharmaceutical packaging industries face growing demands for marking clarity and traceability, CYCJET, brand of Shanghai Yuchang Industrial Co., Ltd., has launched the LU5T mini UV laser printer to deliver high-contrast coding on transparent films, aluminum foil, and colored composite films, while supporting production line integration.
Oct 16 · 01:38·GlobeNewswire
Food & drink
MONTREAL, October 15, 2026--Prime Drink Group Corp. (CSE: PRME) (" Prime " or the " Company ") announces the launch of a proposed private placement financing of subscription receipts for maximum aggregate gross proceeds of CA$4.0 million (the " Financing ") and that it has received a CA$2.5 million le
Oct 15 · 23:56·Business Wire
Food & drink
NEW YORK, Oct. 15, 2026 -- Asti DOCG is bringing the wines, heritage and contemporary spirit of Piedmont to New York this fall as Vinitaly USA returns to the city on October 26–27. Asti DOCG takes over New York at Vinitaly USA, featuring Asti Spumante, Moscato d'Asti and Asti...
Oct 15 · 22:07·PR Newswire
SaaS · Food & drink
Investment in world-scale capacity expansion in India for Globalide® to strengthen global supply
Sustainable macrocyclic musk fragrance ingredient supports customers in developing future-ready fragrance formulations
Globalide® strengthens portfolio of differentiated specialties and supports ONE Symrise strategy
HOLZMINDEN, GERMANY - October 15, 2026 - Symrise is investing in an additional production capacity for Globalide® in India, expanding its global footprint for this strategic fragrance ingredient. The company is thus strengthening its ability to supply a sustainable macrocyclic musk fragrance ingredient and is moving closer to high-growth customer markets. At the same time, Symrise is expanding its Aroma Molecules business in an attractive product segment. The investment supports the ONE Symrise strategy through targeted capital allocation, resilient value creation and profitable growth driven by differentiated ingredients.
“The investment in our Globalide® production footprint underlines our ambition to strengthen strategic product areas that create tangible value for our customers. With this step we are advancing our Scent & Care portfolio. Also, we are generating additional momentum for Symrise’s growth in line with our ONE Symrise strategy,” says Michael Friede, President Scent & Care at Symrise.
Globalide® supports sustainable fragrance concepts
In the fast-growing global fragrance ingredients market, ingredients that combine strong olfactory performance with versatility across applications and modern fragrance creations continue to gain importance. To deliver on this demand, Symrise is investing in additional world-scale production capacity for Globalide® in India. The biodegradable macrocyclic musk ingredient adds long-lasting, elegant notes to fragrances and supports customers in developing more sustainable fragrance formulations.
“With the additional production capacity in India, we are moving closer to the fast-growing markets in Asia while adding another pillar to our long-term global manufacturing footprint,” says Dr Keke Hiller, Global President Aroma Molecules at Symrise. “Globalide® combines high fragrance quality with a contemporary profile. Drawing on our product and technology expertise, we help customers develop attractive, future-ready products for consumers."
Strengthening global supply through targeted investment
By expanding its production footprint, Symrise is further strengthening its position in the market for specialty fragrance ingredients. The additional capacity increases flexibility across the global supply network and provides the foundation for meeting growing demand for Globalide® over the long term. Customers benefit from reliable access to an ingredient that combines high-quality fragrance performance with broad formulation versatility.
About Symrise
Symrise is a global supplier of flavors and fragrances, cosmetic base and active ingredients, and functional ingredients. Its customers include manufacturers of perfume, cosmetics, food, and beverages, as well as the pharmaceutical industry and producers of dietary supplements and pet food.
With sales of around EUR 4.9 billion in the 2025 financial year, the company is one of the world’s leading providers. Headquartered in Holzminden, Germany, the Group has more than 100 sites in Europe, Africa and the Middle East, Asia, North America, and Latin America.
Together with its customers, Symrise develops new ideas and market-ready concepts for products that have become an indispensable part of everyday life. Economic success and corporate responsibility are inextricably linked. Symrise - always inspiring more...
www.symrise.com
Media contact:
Christina Witter
Phone: +49 55 31 90-2182
E-mail: christina.witter@symrise.com
Social media:
linkedin.com/company/Symrise youtube.com/agsymrise
xing.com/companies/symrise instagram.com/symriseag
instagram.com/finefragrancestories_bySymrise instagram.com/symrise.ci
Oct 15 · 21:27·NewMediaWire
Gaming · Food & drink
Denver physician Ozzie Grenardo honors his late daughter with free Broncos tickets, parking and a food gift card for young cancer patients and survivors ages 6-26.
The post Live Love Liv Sends Kids Fighting Cancer to Their First Broncos Game first appeared on
Oct 15 · 21:00·PRUnderground
Food & drink
In the news release, TWO SECRET RECIPES, ONE ICONIC PARTNERSHIP: KFC® U.S. ANNOUNCES NEW BEVERAGE PARTNERSHIP WITH THE COCA-COLA COMPANY, issued 15-Oct-2026 by Kentucky Fried Chicken over PR Newswire, we are advised by the company that a multimedia asset has been added. The complete...
Oct 15 · 20:57·PR Newswire
Food & drink
Patented design fits the sifter beneath the work surface in space-limited kitchens LOUISVILLE, Ky., October 15, 2026--AyrKing, a leading manufacturer of food preparation equipment for commercial kitchens, has received a U.S. patent for its breading and sifting station design. The U.S. Patent and Tradem
Oct 15 · 20:45·Business Wire